Zobrazeno 1 - 10
of 1 814
pro vyhledávání: '"RC254-282"'
Autor:
Julia R. Naso, Stephen Yip, Curtis Hughesman, Barb Melosky, Tanner Dowhy, Melissa K. McConechy, John C. English, Penelope M. A. Brasher, James Choi, Kyle Grant, John Yee, Stephen Lam, Anna McGuire
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 4052-4062 (2024)
Appropriate management requires timely and accurate confirmation of non-small cell lung cancer (NSCLC) recurrence in patients who have had curative-intent surgical resection. We assessed the association between circulating tumor DNA (ctDNA) identifie
Externí odkaz:
https://doaj.org/article/b18337e3aa12439f9926c642c63041ac
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 7, Pp 542-545 (2024)
Since the beginning of the 21st century, the field of cancer drug development has undergone significant changes. Kinase inhibitors are the product category with the highest number of approved drugs and indications. However, despite checkpoint inhibit
Externí odkaz:
https://doaj.org/article/59cb66fbb2d8481a8a59a024a76d64dc
Autor:
Yanli JIA, Xiaoyu LI, Houwu FAN, Wenqing DUAN, Lixia HU, Jian ZHOU, Fengming RAN, Shuang DONG
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 7, Pp 606-612 (2024)
Since the approval of gemtuzumab ozogamicin, an antibody–drug conjugate (ADC) targeting CD33 in 2000, 13 ADC drugs have been approved by the FDA. Although these drugs have clearly improved the survival of patients with various types of advanced can
Externí odkaz:
https://doaj.org/article/d1b6446c6a244a94ae2e77c345cc4045
Autor:
Xin Wu, Chunmei Ban, Woding Deng, Xuewei Bao, Ning Tang, Yupeng Wu, Zhixuan Deng, Jianbin Xiong, Qiangqiang Zhao
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-25 (2024)
Abstract Background Diffuse large B-cell lymphoma (DLBCL) represents a prevalent malignant tumor, with approximately 40% of patients encountering treatment challenges or relapse attributed to rituximab resistance, primarily due to diminished or absen
Externí odkaz:
https://doaj.org/article/ccdf622ccda94fb29dce04252b4e7c60
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background Unlike human epidermal growth factor receptor 2 (HER2) amplification or exon 20 insertions, missense mutations in the extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) of the HER2 protein have
Externí odkaz:
https://doaj.org/article/d225a87f030b47eaa548997d81f75222
Publikováno v:
Cancer Communications, Vol 44, Iss 7, Pp 761-786 (2024)
Abstract Metabolic reprogramming has been demonstrated to have a significant impact on the biological behaviors of tumor cells, among which glycolysis is an important form. Recent research has revealed that the heightened glycolysis levels, the abnor
Externí odkaz:
https://doaj.org/article/9a9f0059a3144ee3963aa52ca157baad
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Exploring the value of baseline and early 18F-FDG PET/CT evaluations in prediction PFS in ER+/HER2- metastatic breast cancer patients treated with a cyclin-dependent kinase inhibitor in combination with an endocrine therapy. Metho
Externí odkaz:
https://doaj.org/article/4cfbbd855fab47abb06113403153df21
Autor:
Arter ZL, Nagasaka M
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 115-121 (2024)
Zhaohui Liao Arter,1,2 Misako Nagasaka1– 3 1Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine
Externí odkaz:
https://doaj.org/article/01ea204cbf0042019b40cefd7897dbbc
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Over the last decades, the therapeutic armamentarium of metastatic renal cell carcinoma (mRCC) has been revolutionized by the advent of tyrosin-kinase inhibitors (TKI), immune-checkpoint inhibitors (ICI), and immune-combinations. RCC is hete
Externí odkaz:
https://doaj.org/article/4924c2725d6f4a3482752f6d917fda30
Autor:
Jeong Uk Lim, Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah. Young Shin, Chang Dong Yeo, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Publikováno v:
Thoracic Cancer, Vol 15, Iss 19, Pp 1513-1521 (2024)
Abstract Background Lazertinib is an oral, third‐generation EGFR‐TKI, which specifically targets the EGFR T790M mutation along with activating mutations Ex19del and L858R. More real‐world data are needed to evaluate its efficacy and safety in t
Externí odkaz:
https://doaj.org/article/4f67126a680b45baa1c45cdf1b84696c